Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Produktmonographie
Produktmonographie von Roche Austria GmbH
Dilatrend - Comprehensive beta1-, beta2- and alpha1-blocking Agent with Ancillary Properties - Indicated for Hypertension, Coronary Heart Disease, Chronic Heart Failure

Produktmonographie (pdf) zum Öffnen/Download (Download: rechte Maustaste und "(Link-)Ziel Speichern unter..." klicken)

Dilatrend - Comprehensive beta1-, beta2- and alpha1-blocking Agent with Ancillary Properties - Indicated for Hypertension, Coronary Heart Disease, Chronic Heart Failure


Dilatrend(R) – the ideal beta-blocking agent: The properties of Dilatrend(R), and the data obtained from numerous experimental and clinical investigations, show that Dilatrend(R) easily fulfils the five key properties of an ideal beta-blocking agent: Comprehensive receptor blockade: Dilatrend(R) is a potent antagonist of the beta1, beta2 and alpha1 adrenergic receptors, with no intrinsic sympathetic activity, and is extremely effective in inhibiting chronic activation of the sympathetic nervous system. Effective and well tolerated across the cardiovascular continuum: The results of many trials in hypertension, CAD, and the large database of the unique Dilatrend(R) clinical trial programme in CHF demonstrate that Dilatrend(R) is effective across the entire cardiovascular continuum. Saves lives: Dilatrend(R)’s unique mode of action does transfer into saving lives. Compared to the conventional beta1-selective beta-blockers metoprolol and bisoprolol, Dilatrend(R) saves more lives as fewer patients need to be treated (number needed to treat (NNT) to save one life. Evidence base: Largest evidence base of any beta-blocker across the full spectrum of CHF. Good tolerability/safety profile: Dilatrend(R) consistently demonstrates fewer, and less serious side-effects than other cardiovascular agents, and is extremely well tolerated. It has demonstrated safety and efficacy in all patient populations, and when used in combination with other agents. Easy to use: Across the cardiovascular continuum, Dilatrend(R) has a practical and simple dosing schedule (once or twice daily), making it easy to use for patients and physicians. Dilatrend(R) amply fulfils all the criteria of the ideal beta-blocking agent.


Diapräsentationen:
Langzeittherapie des Herzinfarktes - Neubewertung der adrenergen Blockade (35 Abbildungen)

Hypertonie als erstes Stadium der Herzinsuffizienz - Chronische adrenerge Überlastung als treibender Faktor für die Progression von Herz-Kreislauf-Erkrankungen (29 Abbildungen)

Mortalitätsstudien bei Herzinsuffizienz: CIBIS II, MERIT-HF, COPERNICUS - Von der Kontraindikation zur Standardtherapie (34 Abbildungen)

COMET - Ergebnisse der längsten und größten Betablockerstudie bei chronischer Herzinsuffizienz (43 Abbildungen)



 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung